REGENXBIO Is Maintained at Buy by Chardan Capital
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)
What 4 Analyst Ratings Have To Say About Regenxbio
Raymond James Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $18
REGENXBIO Price Target Announced at $18.00/Share by Raymond James
Regenxbio Analyst Ratings
Regenxbio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $39 Price Target
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $39
Positive Clinical Trials and Regulatory Milestones Bolster Buy Rating for RegenXBio
Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $50
Regenxbio Analyst Ratings
HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $39
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $39
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
Buy Rating Affirmed for RegenXBio on Strong Clinical Updates and Strategic FDA Engagements
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), RegenXBio (RGNX)
RegenXBio (RGNX) Receives a Buy From Stifel Nicolaus
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), RegenXBio (RGNX) and Laboratory (LH)